Capricor Therapeutics

Health biotech clinics healthtech platform

Capricor Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics for the treatment of diseases. Its lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. As a developer of innovative therapies, Capricor Therapeutics is strategically positioned at the forefront of one of the largest segments of the U.S. healthcare industry − cardiovascular disease.

Revenue(FY, 2017)

$2.7 M

Market capitalization(2018-06-22)

$41 M

Type

Public

Beverly Hills, US

Founded

2005

Size (employees)

29 (est)

Website

capricor.com

Capricor Therapeutics was founded in 2005 and is headquartered in Beverly Hills, US

Report incorrect company information

Key People/Management at Capricor Therapeutics

Linda Marban

President, CEO and Director

Karen Krasney J.D

Executive Vice President and General Counsel

Deborah Ascheim

Chief Medical Officer

Rachel Smith

Vice President of Research and Development

AJ Bergmann M.B.A

CFO

Luis Martinez

Vice President of Regenerative Therapies

Report incorrect company information

Capricor Therapeutics Office Locations

Capricor Therapeutics has an office in Beverly Hills

Beverly Hills, US (HQ)

8840 Wilshire Blvd

Show all (1)

Report incorrect company information

Capricor Therapeutics Financials and Metrics

Capricor Therapeutics Financials

Capricor Therapeutics's revenue was reported to be $2.67 m in FY, 2017

Summary

USD
Revenue (FY, 2017)	2.7 m
Net income (FY, 2017)	2.4 m
EBIT (FY, 2017)	(12.9 m)
Market capitalization (22-Jun-2018)	41 m
Closing share price (22-Jun-2018)	1.4
Cash (31-Dec-2017)	6.1 m

Capricor Therapeutics's current market capitalization is $41 m.

Income Statement

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Revenue	503.2 k	4.8 m	5.5 m	4 m	2.7 m
Revenue growth, %		851%	15%	(28%)
General and administrative expense	2.2 m				4.8 m
R&D expense	5.2 m				10.8 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Revenue	1 m	1 m	1.3 m	1.8 m	1.3 m	1.3 m	1.2 m	1.1 m	746.8 k	880.8 k	996.5 k	313.3 k
General and administrative expense	852.3 k	665.7 k	819.7 k	1.4 m	926.3 k	972.8 k	1.1 m	1.4 m	1.3 m	1.2 m	1.2 m	1.1 m
R&D expense	1.4 m	1.9 m	2 m	3.8 m	3.4 m	3.2 m	4.3 m	4.3 m	4.7 m	3.3 m	3.1 m	1.9 m
Operating expense total	2.2 m	2.5 m	2.8 m	5.2 m	4.4 m	4.2 m	5.4 m	5.7 m	6 m	4.4 m	4.4 m	3 m

show all

Balance Sheet

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Cash	1.7 m	8 m	5.6 m	3.2 m	6.1 m
Accounts Receivable	187
Inventories	222.8 k	235.5 k	210.6 k	342.9 k
Current Assets	3.7 m	11.6 m	14 m	18.1 m	15.7 m

Quarterly

USD	Q1, 2014	Q2, 2014	Q3, 2014	Q1, 2015	Q2, 2015	Q3, 2015	Q1, 2016	Q2, 2016	Q3, 2016	Q1, 2017	Q2, 2017	Q3, 2017
Cash	13 m	11.6 m	9.8 m	6.9 m	5 m	4.2 m	11.8 m	8.9 m	18 m	2.8 m	8.3 m	8.9 m
Accounts Receivable	757	230	823
Inventories												190.3 k
Current Assets	14 m	16.4 m	14.2 m	25.4 m	21.6 m	17.7 m	14.9 m	11.8 m	22.4 m	13.5 m	13.6 m	15.2 m

show all

Cash Flow

Annual

USD	FY, 2013	FY, 2014	FY, 2015	FY, 2016	FY, 2017
Net Income	(8.9 m)	(6.2 m)	(12.9 m)	(18.8 m)	2.4 m
Depreciation and Amortization	26.9 k	41.9 k	110.9 k	125.7 k	144.2 k
Inventories	(161.6 k)	(12.6 k)	24.9 k	(132.3 k)
Accounts Payable	974.7 k	70.3 k	831.2 k	508.3 k	(1.5 m)